Literature DB >> 22152538

Intermediate-term outcomes after paediatric cardiac extracorporeal membrane oxygenation--what is known (and unknown).

John M Costello1, David S Cooper, Jeffrey P Jacobs, Paul J Chai, Roxanne Kirsch, Tami Rosenthal, Heidi J Dalton, Joseph N Graziano, James A Quintessenza.   

Abstract

The use of extracorporeal membrane oxygenation in infants and children with cardiac disease who develop refractory cardiogenic shock, cyanosis, or cardiac arrest is increasing. Early mortality in children with cardiac disease who require extracorporeal membrane oxygenation remains an important issue, as only 40% of cannulated patients survive to discharge from the hospital. However, it is encouraging that 90% children who are discharged alive from the hospital after extracorporeal membrane oxygenation are still alive at intermediate-term follow-up. Surviving patients are at risk for long-term dysfunction of multiple organ systems related to their underlying cardiac disease, non-cardiac comorbidities, treatment-related complications, and exposure to extracorporeal membrane oxygenation. Among the most important acute complications related to support with extracorporeal membrane oxygenation is injury to the central nervous system, which may contribute to adverse neurodevelopmental outcomes. All of these factors, in turn, influence quality of life. Many survivors remain medically complex related to their underlying cardiac disease, comorbidities, and sequelae of complications acquired over their lifetime. Neurological morbidity clearly plays an important role in approximately one-third of survivors, with significant deficits in approximately 10%. The limited data about quality of life data that are available for survivors of cardiac extracorporeal membrane oxygenation suggests that approximately 15-30% of survivors have at least moderately decreased quality of life. Overall, published data support the ongoing use of support with extracorporeal membrane oxygenation in children with acute cardiac failure, most of whom would die without it. However, programmatic efforts to improve the selection of patients and the preservation of the function of end organs during extracorporeal membrane oxygenation are clearly needed in order to improve long-term outcomes.

Entities:  

Mesh:

Year:  2011        PMID: 22152538     DOI: 10.1017/S1047951111001697

Source DB:  PubMed          Journal:  Cardiol Young        ISSN: 1047-9511            Impact factor:   1.093


  4 in total

1.  Biocompatibility Assessment of the CentriMag-Novalung Adult ECMO Circuit in a Model of Acute Pulmonary Hypertension.

Authors:  Venkat Shankarraman; Ergin Kocyildirim; Salim E Olia; Marina V Kameneva; Ryan J Dzadony; Timothy M Maul; Marc A Simon; Hunter C Champion; William R Wagner; Christian A Bermudez
Journal:  ASAIO J       Date:  2014 Jul-Aug       Impact factor: 2.872

2.  Early Neurodevelopmental Outcomes in Children Supported with ECMO for Cardiac Indications.

Authors:  Anjali Sadhwani; Henry Cheng; Christian Stopp; Caitlin K Rollins; Matthew A Jolley; Carolyn Dunbar-Masterson; David Wypij; Jane Newburger; Janice Ware; Ravi R Thiagarajan
Journal:  Pediatr Cardiol       Date:  2019-05-11       Impact factor: 1.655

3.  Using Daily Plasma-Free Hemoglobin Levels for Diagnosis of Critical Pump Thrombus in Patients Undergoing ECMO or VAD Support.

Authors:  James R Neal; Eduard Quintana; Roxann B Pike; James D Hoyer; Lyle D Joyce; Gregory Schears
Journal:  J Extra Corpor Technol       Date:  2015-06

Review 4.  Advances in monitoring and management of shock.

Authors:  Haifa Mtaweh; Erin V Trakas; Erik Su; Joseph A Carcillo; Rajesh K Aneja
Journal:  Pediatr Clin North Am       Date:  2013-03-29       Impact factor: 3.278

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.